| 15.11 -0.28 (-1.82%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 19.89  |
1-year : | 21.37 |
| Resists | First : | 17.03 |
Second : | 18.29 |
| Pivot price | 15.8 |
|||
| Supports | First : | 14.98 |
Second : | 12.47 |
| MAs | MA(5) : | 15.59 |
MA(20) : | 16.08 |
| MA(100) : | 16.06  |
MA(250) : | 15.76 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 11.7 |
D(3) : | 18.1 |
| RSI | RSI(14): 39.3 |
|||
| 52-week | High : | 21.5 | Low : | 11.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ HCM ] has closed above bottom band by 2.7%. Bollinger Bands are 51.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 15.26 - 15.33 | 15.33 - 15.41 |
| Low: | 14.77 - 14.86 | 14.86 - 14.96 |
| Close: | 14.94 - 15.08 | 15.08 - 15.23 |
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
Tue, 14 Oct 2025
HUTCHMED Appoints Professor Tan Shao Weng as Independent Non-executive Director and Technical Committee Member - Quiver Quantitative
Tue, 14 Oct 2025
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee - Stock Titan
Mon, 13 Oct 2025
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress - GlobeNewswire
Thu, 09 Oct 2025
Weiss Ratings Reaffirms Hold (C) Rating for HUTCHMED (NASDAQ:HCM) - MarketBeat
Wed, 01 Oct 2025
Major Cancer Drug Data: HUTCHMED's Fruquintinib Shows Promise in Multiple Cancer Types at ESMO 2025 - Stock Titan
Wed, 01 Oct 2025
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025 - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 172 (M) |
| Held by Insiders | 5.0902e+008 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 404 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 2.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 633.29 |
| Profit Margin | 77.5 % |
| Operating Margin | -1.3 % |
| Return on Assets (ttm) | -0.9 % |
| Return on Equity (ttm) | 46.9 % |
| Qtrly Rev. Growth | -9.2 % |
| Gross Profit (p.s.) | 1.12e+008 |
| Sales Per Share | 1.25458e+009 |
| EBITDA (p.s.) | -1.56042e+007 |
| Qtrly Earnings Growth | 1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -33 (M) |
| PE Ratio | 5.7 |
| PEG Ratio | 0 |
| Price to Book value | 0.02 |
| Price to Sales | 0 |
| Price to Cash Flow | 5.07 |
| Dividend | 0 |
| Forward Dividend | 374510 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|